JS25

• CAT Number: I042579
• CAS Number: 2411771-95-2
• Molecular Formula: C29H24N4O4S
• Molecular Weight: 524.59
• Purity: ≥95%
• Synonyms: N-[3-[8-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-5-methylphenyl]prop-2-enamide
• InChI: InChI=1S/C29H24N4O4S/c1-4-27(34)31-23-13-18(2)14-24(16-23)33-28(35)12-8-21-17-30-26-15-20(7-11-25(26)29(21)33)19-5-9-22(10-6-19)32-38(3,36)37/h4-17,32H,1H2,2-3H3,(H,31,34)
• InChIKey: WPVJPKXENBARHX-UHFFFAOYSA-N
• SMILES: CC1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=C(C=CC4=C32)C5=CC=C(C=C5)NS(=O)(=O)C)NC(=O)C=C

JS25 (Cat No.: I042579) is a novel antibody-drug conjugate (ADC) under investigation for cancer therapy. It targets tumor-specific antigens to deliver a cytotoxic payload directly to malignant cells, aiming to maximize therapeutic efficacy while minimizing harm to healthy tissues. JS25 exemplifies next-generation ADC design, incorporating optimized linkers and potent drug payloads for improved stability and controlled release. Preclinical studies suggest strong antitumor activity, particularly in solid tumors. As research progresses, JS25 holds promise for advancing targeted treatment strategies in oncology.

Reference

[1]. Sousa B B, et al. Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors[J]. ACS Pharmacology & Translational Science, 2022.